Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Highest antigen sequence indentity to the following orthologs: Mouse (87%), Rat (87%).
This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-66281. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
LYRM1 was one of many genes identified through a suppression subtractive hybridization comparing their expression in omental adipose tissue of obese patients compared to non-obese individuals. Further study confirms that both mRNA and protein levels of LYRM1 are higher in obese individuals. LYRM1 is widely expressed, with highest levels occurring in adipose and liver tissues. It is thought that LYRM1 promotes preadipocyte proliferation and can inhibit apoptosis of preadipocytes. Ectopic LYRM1 expression did not significantly affect adipogenesis, suggesting that LYRM1 can influence adipose tissue homeostasis by modulating the size of the preadipocyte pool.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: LYR motif-containing protein 1; unnamed protein product
Gene Aliases: A211C6.1; LYRM1
UniProt ID: (Human) O43325
Entrez Gene ID: (Human) 57149
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support